| Literature DB >> 31314587 |
Yifan Li1,2,3, Shiming He1,3, Yonghao Zhan1,3, Anbang He1,3, Yanqing Gong1,3, Guangjie Ji1,3, Cong Huang1,3, Ding Peng1,3, Bao Guan1,3, Xuesong Li1,3, Liqun Zhou1,3.
Abstract
microRNAs are a class of noncoding RNAs that play important roles in cancer progression. microRNA-183-3p (miR-183-3p) is a novel microRNA that is dysregulated in many kinds of cancers. Our previous studies found high expression and oncologic role of high-mobility group nucleosome binding domain 5 (HMGN5) in prostate cancer. In this study, we found that miR-183-3p was downregulated in prostate cancer cells and primary tissues compared with normal controls. In addition, miR-183-3p expression was negatively correlated with HMGN5 expression. On the basis of bioinformatics predication and quantitative polymerase chain reaction and Western blot verification, it is demonstrated that miR-183-3p regulated HMGN5 expression. Luciferase reporter assay confirmed that miR-183-3p directly targeted the 3'-untranslated region of HMGN5. Interestingly, cell proliferation and migration inhibition and apoptosis induction were also observed in miR-183-3p transfected human prostate cancer VCap and C4-2 cells. Moreover, overexpression of HMGN5 significantly reversed the inhibitory effect on cell proliferation and migration and promoted effect on cell apoptosis by miR-183-3p. Our data suggest that dysfunction of miR-183-3p-HMGN5 axis plays an oncogenic role and can be a therapeutic target for prostate cancer.Entities:
Keywords: HMGN5; microRNA-183-3p; prostate cancer
Mesh:
Substances:
Year: 2019 PMID: 31314587 DOI: 10.1089/dna.2019.4642
Source DB: PubMed Journal: DNA Cell Biol ISSN: 1044-5498 Impact factor: 3.311